• Publications
  • Influence
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Effects of concomitant inhibition of the PI3K/AKT/mTOR pathway and Bcl-2/Bcl-xL (BCL2L1) were examined in human myeloid leukemia cells. Tetracycline-inducible Bcl-2 and Bcl-xL dual knockdown sharplyExpand
  • 122
  • 7
  • PDF
PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo
Purpose: The aim of this study is to explore the efficacy and define mechanisms of action of coadministration of the PI3K/mTOR inhibitor BEZ235 and pan-HDAC inhibitor panobinostat in diffuse largeExpand
  • 60
  • 2
Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation.
Chromodomain helicase DNA-binding protein 4 (CHD4) is an ATPase that alters the phasing of nucleosomes on DNA and has recently been implicated in DNA double-stranded break (DSB) repair. Here, we showExpand
  • 30
  • 2
  • PDF
Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
Interactions between the multikinase inhibitor sorafenib and the BH3-mimetic obatoclax (GX15-070) were examined in human acute myeloid leukemia (AML) cells. Treatment with sorafenib/obatoclax inducedExpand
  • 89
  • 1
  • PDF
Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation
Effects of concurrent inhibition of mTORC1/2 and Bcl-2/Bcl-xL in human acute myeloid leukemia cells were examined. Tetracycline-inducible Bcl-2/Bcl-xL dual knockdown markedly sensitized acute myeloidExpand
  • 15
  • PDF
Co-Administration of the mTORC1/TORC2 Inhibitor INK128 and the Bcl-2/Bcl-Xl Antagonist ABT-737 Kills Human Myeloid Leukemia Cells through Mcl-1 Down-Regulation and AKT Inactivation
Acute myelogenous leukemia (AML) is characterized by frequent aberrations of the PI3K/AKT/mTOR axis steming from diverse mechanisms, including FLT3, Ras, and c-KIT mutations, among multiple others.Expand
  • 9
Inhibition Of PI3K/mTOR By BEZ235 Dramatically Potentiates Panobinostat-Induced Lethality In Diffuse Large B-Cell Lymphoma Through Multiple Mechanisms
Dysregulation of the PI3K/AKT/mTOR pathway and histone deacetylases (HDACs) has been described in diffuse large B-cell lymphoma (DLBCL). Previous studies demonstrated that combined treatment withExpand
  • 2
Abstract 3346: A20/TNFAIP3, a novel target of histone deacetylase inhibitor-induced NF-κB activation, functionally disables the extrinsic apoptotic pathway in human leukemia cells.
The zinc finger protein A20/TNFAIP3 is a novel regulator of the pro-survival NF-κB signaling pathway. TNFα induces A20 via an NF-κB-dependent process to inhibit NF-κB, thus acting as a negativeExpand
Abstract LB-225: E2F1 potentiates proteasome inhibition-mediated cell death in leukemia cells through induction of Noxa
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA While proteasome inhibitors exhibit significant activity in multiple myeloma and lymphoma, the proteasome inhibitor (PI)Expand